Giorgio Valabrega

List of Publications by Year
in descending order

73 papers	2,015 citations	279487 23 h-index	264894 42 g-index
75 all docs	75 docs citations	75 times ranked	3480 citing authors

#	Article	IF	Citations
1	Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences, 2022, 23, 833.	1.8	14
2	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer, 2022, 32, 1205-1207.	1.2	5
3	Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?. International Journal of Molecular Sciences, 2022, 23, 3559.	1.8	15
4	From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia. Frontiers in Oncology, 2022, 12, 859071.	1.3	8
5	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. International Journal of Molecular Sciences, 2022, 23, 5770.	1.8	1
6	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. International Journal of Molecular Sciences, 2021, 22, 4203.	1.8	49
7	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. International Journal of Gynecological Cancer, 2021, 31, ijgc-2020-002343.	1.2	4
8	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	0.8	6
9	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecologic Oncology, 2021, 161, 755-761.	0.6	9
10	The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. Frontiers in Oncology, 2021, 11, 689829.	1.3	9
11	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. International Journal of Gynecological Cancer, 2021, 31, 1363-1368.	1.2	3
12	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. Cells, 2021, 10, 3408.	1.8	4
13	Olaparib as maintenance therapy in patients with BRCA 1â€“2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. Gynecologic Oncology, 2020, 156, 38-44.	0.6	62
14	Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. Cancers, 2020, 12, 2156.	1.7	27
15	Immunotherapy in cervix cancer. Cancer Treatment Reviews, 2020, 90, 102088.	3.4	28
16	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. Cancers, 2020, 12, 2239.	1.7	6
17	Translational Research in Ovarian Cancer. Cancers, 2020, 12, 3676.	1.7	1
18	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. Journal of Ovarian Research, 2020, 13, 53.	1.3	6

#	Article	IF	Citations
19	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers, 2020, 12, 1315.	1.7	18
20	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics, 2020, 10, 146.	1.3	56
21	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 4414.	1.8	87
22	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells, 2020, 9, 442.	1.8	7
23	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. Journal of Gynecologic Oncology, 2020, 31, e92.	1.0	20
24	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. Journal of Clinical Oncology, 2020, 38, e15095-e15095.	0.8	3
25	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. In Vivo, 2019, 33, 2021-2026.	0.6	3
26	Ovarian Cancer Immunotherapy: Turning up the Heat. International Journal of Molecular Sciences, 2019, 20, 2927.	1.8	116
27	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2839.	1.8	34
28	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular Sciences, 2019, 20, 2353.	1.8	24
29	Veliparib: a new therapeutic option in ovarian cancer?. Future Oncology, 2019, 15, 1975-1987.	1.1	9
30	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecologic Oncology, 2019, 153, 535-540.	0.6	19
31	TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. Journal of Ovarian Research, 2019, 12, 17.	1.3	20
32	Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. Scientific Reports, 2019, 9, 3089.	1.6	4
33	Is there a role for immunotherapy in ovarian cancer?. Annals of Translational Medicine, 2019, 7, S276-S276.	0.7	1
34	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. Cancers, 2019, 11, 1820.	1.7	57
35	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. Expert Opinion on Biological Therapy, 2018, 18, 359-367.	1.4	5
36	PARP Inhibitors in Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 392-410.	0.8	102

#	Article	IF	Citations
37	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. Journal of Ovarian Research, 2018, 11, 42.	1.3	21
38	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	0.8	89
39	Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget, 2017, 8, 41143-41153.	0.8	13
40	Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?. Translational Cancer Research, 2017, 6, S197-S200.	0.4	0
41	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. International Journal of Molecular Sciences, 2016, 17, 1169.	1.8	53
42	Adoptive immunotherapy against ovarian cancer. Journal of Ovarian Research, 2016, 9, 30.	1.3	33
43	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 2179-2189.	0.9	9
44	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget, 2016, 7, 4442-4453.	0.8	8
45	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 26181-26191.	0.8	15
46	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2015, 24, 421-431.	1.9	29
47	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. Breast Journal, 2015, 21, 241-245.	0.4	12
48	Recent advances in the development of breast cancer vaccines. Breast Cancer: Targets and Therapy, 2014, 6, 159.	1.0	18
49	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World Journal of Clinical Oncology, 2014, 5, 990.	0.9	87
50	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	2.1	37
51	Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. Oncologist, 2012, 17, 1418-1425.	1.9	79
52	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 2143-2156.	0.9	6
53	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. Annals of Surgical Oncology, 2012, 19, 3755-3761.	0.7	20
54	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 2012, 4, 131.	1.0	12

#	Article	IF	Citations
55	Hormoneâ€receptor expression and activity of trastuzumab with chemotherapy in HER2â€positive advanced breast cancer patients. Cancer, 2012, 118, 17-26.	2.0	58
56	Trastuzumab in the adjuvant setting: a practical review. Therapy: Open Access in Clinical Medicine, 2011, 8, 161-177.	0.2	0
57	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment, 2011, 130, 29-40.	1.1	47
58	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy, 2011, 12, 549-565.	0.9	9
59	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. Oncologist, 2011, 16, 534-536.	1.9	1
60	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer: Targets and Therapy, 2010, 2, 93.	1.0	8
61	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. Oncologist, 2010, 15, 665-672.	1.9	8
62	Trastuzumab Beyond Disease Progression: Case Closed?. Journal of Clinical Oncology, 2009, 27, e121-e122.	0.8	5
63	Multitarget drugs: the present and the future of cancer therapy. Expert Opinion on Pharmacotherapy, 2009, 10, 589-600.	0.9	66
64	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer, 2008, 8, 209.	1.1	8
65	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer, 2008, 8, 436-442.	1.1	25
66	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. Journal of Clinical Oncology, 2008, 26, 2052-2053.	0.8	13
67	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 2007, 7, 257-268.	1.4	96
68	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. Expert Opinion on Pharmacotherapy, 2007, 8, 1179-1188.	0.9	0
69	Trastuzumab Treatment in Breast Cancer. New England Journal of Medicine, 2006, 354, 2186-2186.	13.9	11
70	Outcome of Patients with HER2â€Positive Advanced Breast Cancer Progressing During Trastuzumabâ€Based Therapy. Oncologist, 2006, 11, 318-324.	1.9	116
71	TGFÎ± expression impairs Trastuzumab-induced HER2 downregulation. Oncogene, 2005, 24, 3002-3010.	2.6	113
72	Controversies in breast cancer: adjuvant and neoadjuvant therapy. Expert Opinion on Pharmacotherapy, 2005, 6, 1055-1072.	0.9	5

#	Article	IF	Citations
73	Trastuzumab-based combination therapy for breast cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 81-96.	0.9	43